research

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Authors
    Publication date
    28 June 2016
    Publisher
    BioMed Central
    Doi

      Abstract

      Abstract is not available.

        Similar works

        Full text

        thumbnail-image

        Available Versions

        Springer - Publisher Connector

        redirect
        Last time updated on 30/04/2017